Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 236.75M P/E - EPS this Y -6.30% Ern Qtrly Grth -
Income -22.26M Forward P/E -11.74 EPS next Y -17.10% 50D Avg Chg -9.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 27.00%
Dividend N/A Price/Book 19.13 EPS next 5Y - 52W High Chg -21.00%
Recommedations 1.70 Quick Ratio 2.74 Shares Outstanding 17.77M 52W Low Chg 138.00%
Insider Own 55.33% ROA -69.14% Shares Float 6.42M Beta 0.27
Inst Own 16.53% ROE -168.51% Shares Shorted/Prior 822.55K/766.09K Price 14.79
Gross Margin - Profit Margin - Avg. Volume 67,432 Target Price 22.00
Oper. Margin - Earnings Date May 6 Volume 44,798 Change 7.41%
About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc. News
04/17/24 Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
04/08/24 Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
04/02/24 5 Healthcare Stocks to Buy for 2024
03/21/24 Insider Buys Additional US$51k In Nuvectis Pharma Stock
03/19/24 Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
03/15/24 Nuvectis Pharma to Present at the 36th Annual Roth Conference
03/14/24 Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
03/05/24 Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress
03/05/24 Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
02/19/24 Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership
02/09/24 Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
02/09/24 Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
08:00 AM Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/18/23 Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
11/25/23 Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdings
11/08/23 Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
10/24/23 Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
10/16/23 We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully
10/16/23 Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
09/25/23 Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
NVCT Chatroom

User Image Ronanj Posted - 04/30/24

$NVCT I think today is the day that funds move their final positions from Russel index. We should stabilize soon as the sell pressure diminishes. IMO great day to buy. Good luck to us LONG peeps.

User Image Ronanj Posted - 04/26/24

$NVCT I think that short position, which increased to 822k is the Russel index unwinding its shares ahead of the June reshuffle. If I'm right, then the selling pressure is almost finished. There is positive news ahead. This low stock price is a gift. I'm adding when I have the cash.

User Image Ronanj Posted - 04/24/24

$NVCT adding on thr dips

User Image BioSensai Posted - 04/24/24

$NVCT Loading the boat at this price. Larger data set coming out in the next 3-6 months

User Image BioSensai Posted - 04/23/24

$NVCT This is a $50+ stock in 3 months

User Image JONAME Posted - 04/16/24

$NVCT this is going to hell

User Image essiepaul Posted - 04/09/24

$NVCT cupcake you still hangin tough?

User Image DonCorleone77 Posted - 04/08/24

$NVCT $AZN 2 of 2 - Nuvectis says NXP900 demonstrates robust activity in NSCLC ....Alectinib is the active ingredient in AlecensaTM, an ALK inhibitor approved for the treatment of NSCLC...Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are very pleased to be able to independently confirm the data previously published by the research team at Astra Zeneca, demonstrating the ability of NXP900 to reverse resistance to osimertinib in osimertinib resistant NSCLC cell lines, when administered in combination with osimertinib. We are also pleased with NXP900's potent single-agent activity in NSCLC cells resistant to alectinib."

User Image DonCorleone77 Posted - 04/08/24

$NVCT $AZN 1 of 2 - Nuvectis says NXP900 demonstrates robust activity in NSCLC Nuvectis Pharma (NVCT) recapped poster highlights from the 2024 American Association for Cancer Research AACR conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor EGFR resistant non-small cell lung cancer NSCLC cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca (AZN), demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone. In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase ALK -resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells....

User Image Stock_Titan Posted - 04/08/24

$NVCT Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines https://www.stocktitan.net/news/NVCT/nuvectis-pharma-s-nxp900-demonstrates-robust-activity-in-non-small-3zfw9buol56x.html

User Image oilchaser Posted - 04/04/24

$NVCT ah crap, i angered the shorts with my last comment

User Image johnnygogogo Posted - 04/04/24

$NVCT the next catalyst is this gets de-indexed from the Russell based on the likely market cap threshold. Shorts know this and the forced selling on de-indexation is where they will cover.

User Image oilchaser Posted - 4 weeks ago

$NVCT shorts have forgotten this one today because they are busy ruining other bio stocks. Will they remember tomorrow?

User Image InvestorPlace Posted - 1 month ago

5 Healthcare Stocks to Buy for 2024 $LLY $IBB $NVCT https://investorplace.com/2024/04/5-healthcare-stocks-to-buy-for-2024/

User Image MT_Space_Here Posted - 1 month ago

$NVCT

User Image BioSensai Posted - 03/30/24

$NVCT HOLDING LONG AND STRONG!!

User Image Ronanj Posted - 03/27/24

$NVCT Mr shorty has increased to 766k from 723k.

User Image BioTrade2 Posted - 03/26/24

$NVCT probably stays around this price until the next catalyst. They’re expecting to update both the 800 and the 900 dataset later in the year.

User Image Ronanj Posted - 03/26/24

$NVCT most shares tightly held and not selling. Some bought first the data catalyst release and sold afterwards, those that thought it would recover & bounce back are now disappointed and not willing to wait for next data date. I also believe that Shorty is selling to help drag it down. I am adding because the drug works and the stock price will reflect that one day soon enough. IMO buy and then buy some more.

User Image essiepaul Posted - 03/26/24

$NVCT awful

User Image BioSensai Posted - 03/26/24

$NVCT andd added.

User Image BioSensai Posted - 03/26/24

$NVCT ME STILL HERE!!

User Image Deedawgaz Posted - 03/25/24

$NVCT Haven't heard from our sensai today. Wonder if that pickle is still in this one?

User Image Eko86 Posted - 03/24/24

$NVCT act right tomorrow morning. I got 100k for quick gains

User Image BioSensai Posted - 03/22/24

$NVCT This is going to be a game changing stock. For real tho. last time WHERE DAT 8mm TUMOR GO??!!!!

User Image Ronanj Posted - 03/22/24

$NVCT Google Daniella Thackray. Her story is one that would have a happy ending if she were given NPX8000.

User Image BioSensai Posted - 03/22/24

$NVCT Amber alert for that 8mm tumor

User Image BioSensai Posted - 03/22/24

$NVCT Going completely crazy. WHERE DAT 8MM TUMOR GO?!!! ASKING 4 a FRIEND

User Image BioSensai Posted - 03/22/24

$NVCT FOR REAL!!! SOMEONE GOT DAT 8mm TUMOR HANGING AROUND???!!!!

User Image BioSensai Posted - 03/22/24

$NVCT $50 is too cheap for this

Analyst Ratings
HC Wainwright & Co. Buy Sep 15, 23
HC Wainwright & Co. Buy Mar 7, 23
HC Wainwright & Co. Buy Feb 10, 23
Ladenburg Thalmann Buy Jul 13, 22
HC Wainwright & Co. Buy May 10, 22
HC Wainwright & Co. Buy Mar 2, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BENTSUR RON Chairman & CEO Chairman & CEO Oct 06 Buy 11.23 1,080 12,128 3,236,844 10/10/23
BENTSUR RON Chairman & CEO Chairman & CEO Oct 04 Buy 11.02 3,220 35,484 3,235,764 10/06/23
BENTSUR RON Chairman & CEO Chairman & CEO Aug 15 Buy 14.75 350 5,162 3,232,544 08/16/23
BENTSUR RON Chairman & CEO Chairman & CEO Aug 08 Buy 14.75 300 4,425 3,232,194 08/11/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 31 Buy 13.88 860 11,937 2,595,000 08/01/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 28 Buy 13.91 2,584 35,943 2,594,140 07/31/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 27 Buy 13.98 1,556 21,753 2,591,556 07/28/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 26 Buy 13.97 10,000 139,700 2,590,000 07/27/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 19 Buy 14.84 8,000 118,720 2,571,762 07/20/23
BENTSUR RON Chairman & CEO Chairman & CEO Jul 19 Buy 14.33 200 2,866 3,231,559 07/20/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 18 Buy 14.84 9,149 135,771 2,563,762 07/19/23
BENTSUR RON Chairman & CEO Chairman & CEO Jul 07 Buy 15.61 260 4,059 3,231,359 07/18/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 12 Buy 15.09 3,285 49,571 2,554,613 07/13/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 11 Buy 15.36 10,000 153,600 2,551,328 07/12/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 07 Buy 15.19 8,948 135,920 2,541,328 07/10/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 06 Buy 15.01 3,179 47,717 2,532,380 07/07/23
BENTSUR RON Chairman & CEO Chairman & CEO Jul 06 Buy 14.88 320 4,762 3,231,099 07/07/23
Mosseri Marlio Charles 10% Owner 10% Owner Jul 05 Buy 15.52 1,176 18,252 2,529,201 07/06/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 26 Buy 16.46 16,760 275,870 2,528,025 06/27/23
BENTSUR RON Chairman & CEO Chairman & CEO Jun 26 Buy 16.50 750 12,375 3,230,779 06/27/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 23 Buy 17.43 73,175 1,275,440 2,511,265 06/26/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 21 Buy 17.72 13,090 231,955 2,438,090 06/23/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 16 Buy 17.75 12,700 225,425 2,425,000 06/20/23
Mosseri Marlio Charles 10% Owner 10% Owner Jun 15 Buy 17.63 32,124 566,346 2,412,300 06/16/23
BENTSUR RON Chairman & CEO Chairman & CEO Jun 07 Buy 17.47 350 6,114 3,229,529 06/08/23
BENTSUR RON Chairman & CEO Chairman & CEO May 31 Buy 17.28 330 5,702 3,229,179 06/01/23
BENTSUR RON Chairman & CEO Chairman & CEO May 16 Buy 17.025 320 5,448 3,228,649 05/18/23
BENTSUR RON Chairman & CEO Chairman & CEO Mar 23 Buy 12.13 230 2,790 3,228,329 03/27/23
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Mar 21 Buy 11.99 420 5,036 1,361,955 03/22/23
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Mar 15 Buy 10.71 670 7,176 1,361,535 03/17/23
BENTSUR RON Chairman & CEO Chairman & CEO Nov 30 Buy 7.45 150 1,118 3,015,459 11/30/22
BENTSUR RON Chairman & CEO Chairman & CEO Nov 25 Buy 7.41 450 3,334 3,015,309 11/29/22
BENTSUR RON Chairman & CEO Chairman & CEO Nov 17 Buy 7.24 750 5,430 3,014,859 11/21/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Nov 16 Buy 7.15 300 2,145 1,245,365 11/18/22
BENTSUR RON Chairman & CEO Chairman & CEO Sep 28 Buy 7.35 1,000 7,350 3,013,109 10/03/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Sep 23 Buy 7.87 220 1,731 1,245,065 09/27/22
BENTSUR RON Chairman & CEO Chairman & CEO Sep 23 Buy 7.81 1,500 11,715 3,012,109 09/27/22
BENTSUR RON Chairman & CEO Chairman & CEO Sep 01 Buy 8.24 1,700 14,008 3,010,609 09/06/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Sep 02 Buy 8.31 404 3,357 1,244,845 09/06/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer Aug 31 Buy 8.07 3,006 24,258 1,244,441 09/02/22
BENTSUR RON Chairman & CEO Chairman & CEO Aug 23 Buy 9.04 1,500 13,560 3,008,909 08/30/22
BENTSUR RON Chairman & CEO Chairman & CEO Aug 18 Buy 8.79 19,426 170,755 3,007,409 08/22/22
BENTSUR RON Chairman & CEO Chairman & CEO Jun 28 Buy 11.72 4,000 46,880 2,968,314 06/30/22
BENTSUR RON Chairman & CEO Chairman & CEO Jun 22 Buy 12.23 700 8,561 2,964,314 06/27/22
BENTSUR RON Chairman & CEO Chairman & CEO May 26 Buy 15.82 1,000 15,820 2,963,614 05/31/22
BENTSUR RON Chairman & CEO Chairman & CEO May 19 Buy 17.62 1,200 21,144 2,962,614 05/23/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer May 20 Buy 16.54 300 4,962 1,241,435 05/23/22
BENTSUR RON Chairman & CEO Chairman & CEO May 17 Buy 19.92 2,010 40,039 2,961,414 05/19/22
Shemesh Shay Chief Dev. & Ops. Of.. Chief Dev. & Ops. Officer May 16 Buy 19.42 242 4,700 1,241,135 05/18/22
BENTSUR RON Chairman & CEO Chairman & CEO May 13 Buy 18.71 1,700 31,807 2,959,404 05/17/22